GSK Performance momentum, outlooks for growth and returns
Overig advies
05/02/2025 08:30
Strong track record of
performance since demerger
Attractive portfolio and pipeline of
Specialty Medicines and Vaccines
• Outlooks consistently improving
• Quality of pipeline (FIC/BIC1
) increased
• Year-on-year delivery sustained
• Profitability improvements made and
remain key focus
• Transformed balance sheet and
stronger cash generation now evident
• Delivering performance whilst investing
for growth
See & read more on
https://www.gsk.com/media/11774/fy-2024-results-slides.pdf
Beperkte weergave ! Leden hebben toegang tot meer informatie! Omdat u
nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt
daarom GRATIS Lid of login
met uw wachtwoord